CANDONI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 15.108
NA - Nord America 13.307
EU - Europa 6.792
SA - Sud America 1.622
Continente sconosciuto - Info sul continente non disponibili 390
AF - Africa 214
OC - Oceania 44
Totale 37.477
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.934
CN - Cina 5.260
SG - Singapore 4.035
IT - Italia 2.166
HK - Hong Kong 1.779
GB - Regno Unito 1.369
BR - Brasile 1.275
KR - Corea 978
VN - Vietnam 950
FI - Finlandia 897
BD - Bangladesh 894
RU - Federazione Russa 389
DE - Germania 386
SE - Svezia 345
FR - Francia 338
IN - India 255
ID - Indonesia 242
NL - Olanda 212
CA - Canada 158
LT - Lituania 129
JP - Giappone 128
AR - Argentina 127
MX - Messico 118
TR - Turchia 112
UA - Ucraina 112
IQ - Iraq 101
IE - Irlanda 69
AT - Austria 64
AE - Emirati Arabi Uniti 53
ZA - Sudafrica 53
EC - Ecuador 52
PK - Pakistan 47
BG - Bulgaria 46
ES - Italia 43
AU - Australia 42
CO - Colombia 40
CZ - Repubblica Ceca 39
PL - Polonia 37
VE - Venezuela 32
CL - Cile 29
SA - Arabia Saudita 29
UZ - Uzbekistan 28
KE - Kenya 26
TN - Tunisia 26
EG - Egitto 25
MA - Marocco 25
PY - Paraguay 25
TW - Taiwan 24
MY - Malesia 22
NP - Nepal 18
PH - Filippine 18
TH - Thailandia 18
DZ - Algeria 17
PT - Portogallo 17
CH - Svizzera 16
UY - Uruguay 16
JM - Giamaica 15
PE - Perù 15
JO - Giordania 14
RO - Romania 14
BE - Belgio 13
CR - Costa Rica 13
GT - Guatemala 13
HN - Honduras 13
IL - Israele 13
OM - Oman 13
BY - Bielorussia 11
BO - Bolivia 10
DO - Repubblica Dominicana 10
GR - Grecia 10
HU - Ungheria 10
DK - Danimarca 9
KZ - Kazakistan 9
TT - Trinidad e Tobago 9
AZ - Azerbaigian 8
AL - Albania 7
HR - Croazia 7
NI - Nicaragua 7
PS - Palestinian Territory 7
SY - Repubblica araba siriana 7
AO - Angola 6
EU - Europa 6
KG - Kirghizistan 6
QA - Qatar 6
SK - Slovacchia (Repubblica Slovacca) 6
IR - Iran 5
RS - Serbia 5
SV - El Salvador 5
BA - Bosnia-Erzegovina 4
ET - Etiopia 4
LB - Libano 4
LV - Lettonia 4
MD - Moldavia 4
MN - Mongolia 4
NO - Norvegia 4
UG - Uganda 4
BB - Barbados 3
BH - Bahrain 3
BN - Brunei Darussalam 3
CI - Costa d'Avorio 3
Totale 37.031
Salva come PNG Salva come JPEG
Città #
Hefei 3.388
Singapore 2.427
Santa Clara 1.878
Ashburn 1.717
Hong Kong 1.681
San Jose 1.177
Seoul 971
Helsinki 816
London 695
Council Bluffs 674
Fairfield 511
The Dalles 438
Southend 381
Los Angeles 364
Ho Chi Minh City 330
Beijing 320
Milan 285
Houston 277
Woodbridge 260
New York 256
Chicago 245
Seattle 228
Lauterbourg 221
Hanoi 208
Kent 197
Chandler 195
Nyköping 191
Buffalo 185
Jakarta 180
Wilmington 177
Dallas 171
Rome 165
Cambridge 159
Ann Arbor 158
Boardman 135
Jacksonville 131
São Paulo 130
Moscow 115
Dearborn 114
Munich 107
Salt Lake City 95
Shanghai 94
Amsterdam 90
Redondo Beach 81
Columbus 76
Modena 73
San Diego 71
Bologna 68
Dublin 68
Frankfurt am Main 68
Nuremberg 62
Tokyo 62
Mexico City 59
Reggio Emilia 57
Tampa 55
Elk Grove Village 54
Da Nang 51
Delhi 51
Atlanta 48
Washington 47
Phoenix 45
Brooklyn 44
Guangzhou 44
Hillsboro 42
Princeton 41
Sofia 40
Naples 39
North Bergen 39
Rio de Janeiro 39
Baghdad 38
Miami 37
Turin 37
Belo Horizonte 36
Boston 36
Florence 36
Miano 36
Izmir 35
Toronto 35
Orem 34
Kilburn 30
Lappeenranta 30
Eugene 29
Montreal 29
Mumbai 29
Charlotte 27
Palermo 27
Shenzhen 27
Vienna 26
Warsaw 26
Brasília 25
Curitiba 25
Haiphong 25
Johannesburg 25
Sterling 25
Biên Hòa 24
Des Moines 24
Tashkent 24
Turku 24
Bari 23
Guarulhos 23
Totale 24.868
Salva come PNG Salva come JPEG
Nome #
Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients 432
Mucorales-specific T cells in patients with hematologic malignancies 367
A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients 356
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 343
invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. 321
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial 318
Anagrelide in Essential Thrombocythemia: A Retrospective Analysis of 220 Patients. Session Type: Poster Session 646-III 313
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) 303
The Role of Wilms’ Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia 293
Identification and characterization of Aspergillus-specific immune responses to diagnose invasive aspergillosis in high risk patients: a multicenter study 275
Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia 273
Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia 267
Mucorles-specific T cells emerge in the course of invasive mucormucosis and may be used as a surrogate diagnostic marker in high-risk patients 263
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study 262
European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group 262
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers 257
PEG Intron in Essential Thrombocythemia: Two Years Treatment in 90 Patients. 255
Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: Feasibility and utility (SEIFEM-2008B study) 253
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 241
Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation 240
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. 234
PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study. 227
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data 225
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) 221
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. 220
Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results. 219
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey 217
Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies 217
PEG Interferon a-2b (PEG-Intron) in Essential Thrombocythemia: Phase II Study for Determination of the Minimum Effective, Safe and Tolerated Dose. Preliminary Data. 216
Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management 216
Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use 213
SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy 207
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 203
Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. 203
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 200
Bone marrow biopsy and aspirate evaluation in 90 patients with Essential Thrombocythemia treated with PEG interferon alpha-2b. Preliminary results 198
Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study 192
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study 191
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 189
Pneumocystis jirovecii pneumonia at chest High-resolution Computed Tomography (HRCT)in non-HIV immunocompromised patients: Spectrum of findings and mimickers 188
10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG 188
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 186
Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical ventilation and mortality in seronegative and seropositive patients 185
Intravascular lymphoma: Clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant' 184
Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program 183
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial 182
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study 181
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature 179
Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience 178
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience 176
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia 170
Advanced mast cell disease: An Italian Hematological Multicenter experience 167
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia 167
Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: An Italian multicentre prospective survey 165
Acute myeloid leukemia in patients previously diagnosed with breast cancer: Experience of the GIMEMA group 164
COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit 164
Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry 163
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma 158
Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial 158
PEG Interferon alpha2b (PEG Intron) in Essential Thrombocytemia: Phase II Study for Determination of the Minimun Effective, Safe and Tolerated Dose. Preliminary Data. 157
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 157
Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia 155
Antibody Binding Capacity for Evaluation of MDR-Related Proteins in Acute Promyclocytic Leukemia: Onset Versus Relapse Expression 153
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 152
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE) 150
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 150
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 150
Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax 148
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 148
Systemic antifungal treatment after posaconazole prophylaxis: Results from the SEIFEM 2010-C survey 145
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy 145
Identification and validation of diagnostic cut-offs of the ELISpot assay for the diagnosis of invasive aspergillosis in high-risk patients 145
FLAI induction regimen in elderly patients with acute myeloid leukemia 144
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial 144
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 143
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia 143
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 143
Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination 142
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy 142
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial 141
Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia 139
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study 139
Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study 139
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 138
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO) 138
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia 138
Real-Time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: Results from a prospective, monocentric, interventional study 138
Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study 134
Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey 133
A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia 133
Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series 132
Revision of antifungal strategies definitions for invasive fungal infections (proven/probable/possible) in 461 patients with haematological malignancies (REDEFI-SEIFEM) 132
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 130
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia 130
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax 129
Fungaemia in haematological malignancies: SEIFEM-2015 survey 128
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 127
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia 126
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience 126
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts 126
Totale 19.140
Salva come PNG Salva come JPEG
Categoria #
all - tutte 194.348
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 194.348
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022691 0 101 59 44 30 57 34 42 87 52 90 95
2022/20231.245 79 47 43 53 88 87 319 130 200 28 72 99
2023/20242.253 58 67 144 201 370 187 325 230 54 65 223 329
2024/20259.165 218 117 96 624 1.549 1.063 390 347 1.016 886 1.539 1.320
2025/202620.269 1.801 1.492 2.461 2.005 1.240 1.267 2.716 854 1.550 1.661 1.641 1.581
2026/20271.074 854 220 0 0 0 0 0 0 0 0 0 0
Totale 37.477